Immunic, inc. announces 200 patients enrolled in its phase 2 calvid-1 trial of imu-838 for the treatment of moderate covid-19, allowing for main phase 2 efficacy analysis to proceed

New york, nov. 2, 2020 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that the company has enrolled and...
IMUX Ratings Summary
IMUX Quant Ranking